Betamethasone phonophoresis to help repigment vitiligo patches
Official title: Effect of Betamethasone Phonophoresis in Treatment of Vitiligo
Run by Cairo University · NCT07267273 · Data updated 2026-11-12
This trial will try using betamethasone delivered with therapeutic ultrasound (phonophoresis) to help people with vitiligo regain skin pigment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 25 Years to 40 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | November 10, 2025 |
| Main results expected | February 1, 2026 |
| Study ends | February 10, 2026 |
| Registry record updated | December 5, 2025 |
| Trial ID | NCT07267273 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are medically and psychologically stable adults with vitiligo who can consent, have no contraindication to therapeutic ultrasound, and are not on systemic immunosuppressants or phototherapy.
✕Probably not a fit
Patients who are pregnant or lactating, immunosuppressed, have active skin infections, are receiving systemic immunosuppressants or phototherapy, or have unstable/progressive disease are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study applies a mid-potency topical corticosteroid (betamethasone) using therapeutic ultrasound (phonophoresis) to enhance skin penetration at sites of vitiligo. Eligible patients will attend treatment sessions at Cairo University Hospital and be followed over time with clinical exams and standardized photographs to document repigmentation and side effects. The study will monitor for local and systemic steroid adverse events and exclude patients with pregnancy, active infections, systemic immunosuppression, or current phototherapy. Treatment response will be measured as change in pigmentation of enrolled lesions compared with baseline.
Why it matters
Potential benefit: If successful, this approach could improve repigmentation of vitiligo patches by increasing local steroid delivery while minimizing systemic exposure.
How similar studies have gone: Phonophoresis has been used to boost topical drug delivery in other conditions, but its specific benefit for vitiligo is novel with limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female patients diagnosed with vitiligo. * Medically and psychologically stable patients. * Good cognitive abilities to understand the requirements of the study. * All patients enrolled to the study will have their informed consent. * they had no contraindications to the use of therapeutic ultrasound Exclusion Criteria: * Pregnancy or lactation. * Immunosuppression. * Alcohol abuse. * History of spontaneous re-pigmentation of lesions. * Presence of skin characteristics that may interfere with study assessment. * Active bacterial/viral infection. * Patients on other immune suppressants and phototherapy * Patients currently participating in any other clinical study * Uncooperative patients.
Where it's running
-
Cairo University Hospital
Cairo, Egypt Recruiting
Study contacts
- Study coordinator: Ola Sabry Abd-Elmaksoud Tarabya, MSc
- Email: Olasabry17@yahoo.com
- Phone: +201024035447
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo
This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.
-
Imaging vitiligo lesions with polarized, sub-ultraviolet, and ultraviolet dermoscopy
This study tests whether advanced light-based skin imaging can reveal details of vitiligo spots in adults more clearly than standard polarized dermoscopy.
-
MH004 Ointment in non-segmental vitiligo: a phase 3 trial
A 12-month randomized trial tests MH004 ointment to see if it helps facial vitiligo more than a placebo in people aged 12 to 75.
-
NSV: Vitiligo Drug Safety and Effectiveness Registry for Adults and Teens
This registry tracks adults and teens with nonsegmental vitiligo to see how usual treatments work and how safe they are over time in real-world dermatology care.
-
D-2570 in Non-Segmental Vitiligo (Phase 2)
This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.
-
LY4005130 for adults with non-segmental vitiligo
This study will test whether intravenous LY4005130 is safe and what side effects it may cause in adults with non-segmental vitiligo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.